Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.91 USD | -3.41% |
|
+5.33% | +31.52% |
Feb. 13 | Travere Therapeutics Insider Sold Shares Worth $1,356,100, According to a Recent SEC Filing | MT |
Feb. 11 | Sector Update: Health Care Stocks Fall in Late Afternoon Trading | MT |
Capitalization | 1.99B 1.9B 1.79B 1.58B 2.83B 173B 3.13B 21.32B 7.9B 72.23B 7.47B 7.32B 303B | P/E ratio 2024 * |
-6.2x | P/E ratio 2025 * | -17.6x |
---|---|---|---|---|---|
Enterprise value | 2.05B 1.95B 1.84B 1.63B 2.91B 178B 3.23B 21.95B 8.13B 74.38B 7.7B 7.54B 312B | EV / Sales 2024 * |
8.88x | EV / Sales 2025 * | 5.53x |
Free-Float |
98.88% | Yield 2024 * |
-
| Yield 2025 * | - |
Last Transcript: Travere Therapeutics, Inc.
1 day | -3.41% | ||
1 week | +5.33% | ||
Current month | +11.97% | ||
1 month | +34.21% | ||
3 months | +24.04% | ||
6 months | +168.58% | ||
Current year | +31.52% |







Director | Title | Age | Since |
---|---|---|---|
Eric Dube
CEO | Chief Executive Officer | 52 | 2019-01-03 |
Chris Cline
DFI | Director of Finance/CFO | 41 | 2022-08-30 |
Jula Inrig
CTO | Chief Tech/Sci/R&D Officer | 50 | 2022-01-03 |
Manager | Title | Age | Since |
---|---|---|---|
Gary Lyons
CHM | Chairman | 74 | 2016-05-17 |
Jeffrey Meckler
CHM | Chairman | 58 | 2015-06-07 |
Tim Coughlin
BRD | Director/Board Member | 58 | 2015-03-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.15% | 0 M€ | 0.00% | - | |
0.12% | 0 M€ | 0.00% | - |
Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
---|---|---|---|---|---|---|
-3.41% | +5.33% | +177.70% | -18.15% | 1.99B | ||
-0.77% | -2.20% | +9.84% | +98.50% | 118B | ||
-0.10% | -5.13% | -28.93% | +8.03% | 72.09B | ||
-2.13% | -3.83% | +68.23% | +140.90% | 38.79B | ||
-2.40% | +1.89% | +31.02% | -22.46% | 28.73B | ||
+2.38% | +3.29% | +58.26% | +12.45% | 24.63B | ||
+4.61% | +2.25% | +11.97% | -30.27% | 23.61B | ||
-2.06% | +6.27% | +380.22% | +952.71% | 15.76B | ||
+0.81% | -0.80% | +189.03% | +244.83% | 14.19B | ||
+0.94% | +8.59% | -19.89% | -31.61% | 13.46B | ||
Average | -0.21% | +1.49% | +87.74% | +135.49% | 35.11B | |
Weighted average by Cap. | -0.28% | -1.12% | +37.28% | +98.62% |
2024 * | 2025 * | |
---|---|---|
Net sales | 231M 220M 208M 183M 327M 20.02B 363M 2.47B 915M 8.37B 866M 849M 35.15B | 362M 344M 325M 287M 513M 31.34B 569M 3.87B 1.43B 13.11B 1.36B 1.33B 55.02B |
Net income | -291M -277M -261M -231M -412M -25.21B -458M -3.11B -1.15B -10.54B -1.09B -1.07B -44.26B | -117M -111M -105M -92.65M -166M -10.12B -184M -1.25B -463M -4.23B -438M -429M -17.77B |
Net Debt | 59.43M 56.58M 53.36M 47.13M 84.21M 5.15B 93.44M 635M 235M 2.15B 223M 218M 9.04B | 7.1M 6.76M 6.38M 5.63M 10.06M 615M 11.16M 75.91M 28.12M 257M 26.62M 26.08M 1.08B |
Date | Price | Change | Volume |
---|---|---|---|
25-02-14 | 22.91 $ | -3.41% | 1,467,097 |
25-02-13 | 23.72 $ | +2.24% | 1,884,279 |
25-02-12 | 23.20 $ | -2.32% | 2,787,440 |
25-02-11 | 23.75 $ | +12.56% | 6,409,820 |
25-02-10 | 21.10 $ | -2.99% | 1,796,272 |
Delayed Quote Nasdaq, February 14, 2025 at 04:00 pm EST
More quotes
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- TVTX Stock